Plunkett Consulting, on behalf of our international client, has been assigned Orphan Drug Designation by the Therapeutic Goods Administration (TGA) for a new treatment malignant pleural mesothelioma currently in development. As part of  this collaboration, Plunkett Consulting has prepared and submitted a comprehensive Orphan Drug Designation application to the TGA, that provides a detailed overview